Metronidazole Powder

Nitroreduction: Metronidazole is inactive in its prodrug form but becomes activated in the low-oxygen (anaerobic) environment of bacterial cells.

Enzymatic Activation: Anaerobic bacteria (e.g., Bacteroides, Clostridium, Fusobacterium) contain nitroreductase enzymes that reduce the nitro group (-NO₂) on metronidazole to a highly reactive nitroso radical (-NO).

DNA Damage: The nitroso radical interacts with bacterial DNA, causing strand breaks and inhibition of nucleic acid synthesis, leading to cell death.

Trichomonas vaginalis: Metronidazole disrupts the DNA of this protozoan parasite, similar to its action against bacteria.

Giardia lamblia: It inhibits cysteine protease enzymes essential for parasite survival.

Entamoeba histolytica: Metronidazole targets trophozoites, preventing tissue invasion.

Metronidazole's efficacy is limited to anaerobic organisms because aerobic bacteria lack the enzymes required for its activation. This selectivity minimizes harm to human cells and beneficial aerobic flora.

Immune factors: low cellular immunity, autoimmune disorders (such as Behcet's disease), and decreased mucosal repair ability.
Trauma factors: physical injuries such as bites, sharp tooth tips, food scratches, and friction between braces.

Clinical classification (3 core types)
Mild recurrent aphthous ulcer (most common, accounting for 80%): diameter 5-10mm, round/oval, with a red halo at the edges and a yellow white pseudomembrane in the center, obvious pain, self healing within 7-14 days, without leaving scars; There is often no obvious infection, and metronidazole is only used for secondary infections.

Severe recurrent aphthous ulcer (periglandular type, accounting for 10%): diameter>1cm, deep into the submucosal layer, severe pain, slow healing (weeks to months), scar formation; Easy to merge with anaerobic bacterial infections, metronidazole is an important adjuvant drug.
Herpetic ulcers (10%): diameter<5mm, number>10, clustered distribution, widespread congestion, severe pain, accompanied by low-grade fever and fatigue; Often accompanied by infections, metronidazole can control inflammation.

Radiation and chemotherapy injury (core): Chemotherapy drugs (such as 5-FU, methotrexate) and head and neck radiotherapy directly damage mucosal epithelial cells, inhibit cell division, and lead to mucosal atrophy, erosion, and ulceration.
Infection (key aggravating factor): After the mucosal barrier is disrupted, oral anaerobic bacteria, aerobic bacteria, and fungi invade, causing secondary infections, significantly exacerbating inflammation, pain, and ulcers, and prolonging healing time; 

Applicable scenarios of metronidazole (precise matching)
Oral ulcers: recurrent ulcers, severe ulcers, herpetic ulcers, postoperative infectious ulcers, and secondary infections of traumatic ulcers with concurrent anaerobic bacterial infections.
Oral mucositis: Secondary anaerobic bacterial infection, radiation stomatitis, and mucosal erosion with odor/purulent discharge after chemotherapy and radiotherapy for grade II-IV mucositis.

Inhibiting the release of inflammatory mediators
Metronidazole can inhibit neutrophil chemotaxis and aggregation, reduce the release of inflammatory mediators such as prostaglandins, leukotrienes, tumor necrosis factor - α (TNF - α), interleukin-6 (IL-6), and alleviate mucosal congestion, edema, burning sensation, and pain.

Immune regulatory effect (enhancing mucosal resistance)
Metronidazole can regulate the local immune microenvironment: reduce pro-inflammatory factors, increase anti-inflammatory factors (IL-10), enhance macrophage phagocytic function, inhibit abnormal immune responses, promote immune balance, and reduce ulcer recurrence.

Promote mucosal repair (accelerate healing, shorten the course of the disease)
Improving Local Microenvironment
By eliminating anaerobic bacteria, controlling inflammation, reducing toxins, and eliminating obstacles to mucosal repair, favorable conditions are created for epithelial cell regeneration.

Gynecological Infections: It is effective in treating bacterial vaginosis, a common vaginal infection caused by an overgrowth of anaerobic bacteria. Metronidazole can be administered orally or vaginally (using suppositories prepared from the powder in some cases) to restore the normal vaginal flora.

Skin and Soft Tissue Infections: In cases of skin and soft tissue infections with anaerobic involvement, such as necrotizing fasciitis, metronidazole can be used as part of the multi - drug therapy to control the infection.

Amebiasis: Metronidazole is the drug of choice for the treatment of intestinal and extraintestinal amebiasis caused by Entamoeba histolytica. It can eliminate the trophozoites in the intestinal lumen and also reach the liver to treat hepatic amebic abscesses.

Trichomoniasis: It is highly effective against Trichomonas vaginalis, the causative agent of trichomoniasis, a sexually transmitted infection.

Common gastrointestinal adverse effects of metronidazole include nausea, vomiting, diarrhea, and abdominal discomfort. These symptoms are usually mild and transient, but in some cases, they can be severe enough to require discontinuation of the drug. Taking the medication with food can help reduce the incidence of these side effects.

Metronidazole can cause neurological side effects, especially with high - dose or long - term use. These may include peripheral neuropathy, characterized by numbness, tingling, and pain in the extremities. In rare cases, it can cause seizures, encephalopathy, and optic neuropathy. Patients with pre - existing neurological conditions may be at a higher risk of developing these adverse effects.

Metronidazole can rarely cause hematological abnormalities such as leukopenia, neutropenia, and thrombocytopenia. Regular blood counts may be required in patients receiving long - term treatment, especially those with pre - existing hematological disorders.

Some patients may experience metallic taste in the mouth, dark urine (due to the excretion of metabolites), and allergic reactions such as rash, itching, and anaphylaxis.